Submitted by Novo Nordisk
Next week, world leaders will launch a new round of goals, targets and indicators to pick up where the Millennium Development Goals left off. In the new issue of Novo Nordisk’s sustainability magazine – TBL Quarterly – the company shows how improving the prevention and treatment of type 2 diabetes plays a key role in achieving many of the 17 new Sustainable Development Goals (SDGs).
The SDGs will guide United Nations member states in framing their agendas and political policies over the next 15 years. The latest TBL Quarterly, Global health check – Are we in shape for the next 15 years? shares stories of initiatives that have contributed to reducing maternal mortality and improving access to diabetes care and shows how additional efforts contributes to many of the 17 new SDGs.
“There is a very large opportunity to create shared value when both governments, NGOs and companies like Novo Nordisk are working towards the same goals,” says Charlotte Ersbøll, corporate vice president, Corporate Stakeholder Engagement, Novo Nordisk. “Type 2 diabetes has become both a developing and developed country challenge and the SDGs make a clear call to action for all of us to work together.”
The TBL Quarterly is published four times a year. If you want to receive notification when new issues are available, send a mail to firstname.lastname@example.org.
About the TBL Quarterly
Novo Nordisk manages its business in accordance with the Triple Bottom Line (TBL) business principle and pursues business solutions that maximise value to both the company and its stakeholders. Through selected themes, new perspectives and personal stories, the TBL Quarterly demonstrates how our TBL business principle supports long-term value creation. The TBL Quarterly is available as a reader-friendly PDF.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has also given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
Novo Nordisk strives to conduct its activities in a financially, environmentally and socially responsible way. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today’s business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.
More from Novo Nordisk